Clinical Observation of the Performance of Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line in Treatments of Patients With End-Stage Renal Disease (ESRD)

NCT03859830 | Completed

• 1 other identifier: BXU012184
• Study Type: interventional
• Target: 276
• Locations: 1 country
• Sites: 7

Brief Summary

The incidence and prevalence of chronic kidney disease are increasing worldwide, as is the number of patients progressing to End-Stage Renal Disease (ESRD). China has experienced an increased accessibility and affordability of dialysis treatment, which in turn has brought about an increase in the number of patients receiving Renal Replacement Therapy (RRT).Without RRT, either in the form of maintenance dialysis or transplantation, ESRD is fatal. The scope of the trial is to observe the performance of Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line versus AK 200 Ultra S, extracorporeal circulation conduct of blood purification apparatus and Ultra Steriset as the comparator devices in treatment of patients using hemodialysis (HD) or hemodiafiltration (HDF) for ESRD.

Conditions

End-Stage Renal Disease

Outcome Measures

Primary Outcomes (3)

• Number of participants successfully completing HDF without interruption of therapy during Dialysis

  Defined as participants not having an interruption in therapy for greater than 15 continuous minutes due to a technical reason of all the enrolled patients in the same group. If there is more than one interruption due to technical reasons, the criteria for failure should be the sum of all interruptions being greater than 15 minutes.

  Day 1 (One Midweek HDF Treament Session, 4 hour duration)

• Number of Participants by Level of Effectiveness of Disposable Tubing during and after Dialysis

  Participant recorded as "yes" or "no" by categories of (1) blood flow in the tubing is smooth without obstruction, blood flow rate meets requirement of the patient's hemodialysis prescription and finish the dialysis procedure, the (2) connections are free from blood and air leakage and detachment, (3) there is no folding, cracking or rupture in tubing during dialysis procedure.

  Day 1 (One Midweek HDF Treament Session, 4 hour duration)

• Reduction ratio of β2-Microglobulin during and after Dialysis

  Day 1 (One Midweek HDF Treament Session, 4 hour duration)

Secondary Outcomes (4)

• Single-pool Kt/V urea during and after Dialysis

  Day 1 (One Midweek HDF Treament Session, 4 hour duration)

• Urea Reduction Ratio (URR) during and after Dialysis

  Day 1 (One Midweek HDF Treament Session, 4 hour duration)

• Number of Participants by Level of Appearance of Disposable Tubing during and after Dialysis

  Day 1 (One Midweek HDF Treament Session, 4 hour duration)

• Number of Participants by Level of Elasticity of Pump Lines during and after Dialysis

  Day 1 (One Midweek HDF Treament Session, 4 hour duration)

Study Arms (2)

Artis Dialysis System

EXPERIMENTAL

One midweek HDF session for a duration of 4 hours.

Device: Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line

AK200 Ultra S

ACTIVE COMPARATOR

One midweek HDF session for a duration of 4 hours.

Device: AK200 Ultra S, extracorporeal circulation conduct of blood purification

Interventions

Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line DEVICE

The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

Artis Dialysis System

AK200 Ultra S, extracorporeal circulation conduct of blood purification DEVICE

The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

AK200 Ultra S

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients ≥18 to ≤75 years of age with diagnosis of ESRD
• Patients on thrice weekly HD for a minimum of 3 months who received at least one 4 hour HDF treatment in the past two weeks prior to study enrollment with a total convection volume (VCtot) (including UF) of equal or greater than 16 L post-dilution
• Body weight (BW) ≥ 40 Kg
• Patients with stable dialysis profiles:
• Kt/Vurea ≥ 1.2 which is taken within 4 weeks before study enrollment
• Dialysis prescription stable over 6 recent treatments
• Patients on stable anticoagulation dose
• Patients who have an adequate arteriovenous fistula (AVF) or graft, capable of providing a QB with 200-300 mL/min range
• Patients able to give informed consent (IC) after an explanation of the proposed study
• Patients who receive in-center treatment HD at a site that routinely implements high flux dialysis and/or HDF

You may not qualify if:

• Patients who are human immunodeficiency virus (HIV) positive, or with active Hepatitis A (HAV), Hepatitis B (HBV) or Hepatitis C (HBC)
• Patients with known hemodynamic instability, bleeding risks and coagulation disorders
• Patients with active or ongoing infection
• Patients with advanced liver, heart or pulmonary disease, as judged by the Investigator, that would not be suitable for participation in the study
• Patients with any comorbidity possibly conflicting with the study purpose or procedures as judged by the Investigator
• Patients who are currently participating in other interventional clinical trials or have participated in another interventional clinical trial within one (1) month of the current study that may interfere with this study as judged by the Investigator.
• Pregnant women, lactating women and women or men who plan to have a baby and refuse to apply the effective contraceptive methods during the study period
• Patients with active cancer
• Patients who have acute renal failure
• Patients who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to PD within the next two months, or who require single needle dialysis therapy
• Patients diagnosed with New York Heart Association (NYHA) Class IV congestive heart failure, or acute coronary syndrome and/or who have suffered a myocardial infarction within the three months prior to the start of the study
• Patients with a history of severe mental disorders
• Patients who have had an allergic response to polyarylethersulfone or polysulfone membrane

Sponsors & Collaborators

• Vantive Health LLC: lead
• Baxter Healthcare Corporation: collaborator

Study Sites (7)

Investigational Site

Beijing, Beijing Municipality, 100730, China

Location

Investigational Site

Foshan, Guangdong, 528000, China

Location

Investigational Site

Wuhan, Hubei, 430060, China

Location

Investigational Site

Nanjing, Jiangsu, 210009, China

Location

Investigational Site

Shenyang, Liaoning, 110001, China

Location

Investigational Site

Hangzhou, Zhejiang, 310003, China

Location

Investigational Site

Wenzhou, Zhejiang, 325003, China

Location

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, Chronic; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2019
• First Posted: March 1, 2019
• Study Start: January 22, 2019
• Primary Completion: November 9, 2019
• Study Completion: November 9, 2019
• Last Updated: March 13, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (7)